Determination of Frequency of Epstein-Barr Virus in Non-Hodgkin Lymphomas Using EBV Latent Membrane Protein 1 (EBV-LMP1) Immunohistochemical Staining

  • Ishtiaq, Sheeba (Department of Pathology, Shaukat Khanum Cancer Hospital) ;
  • Hassan, Usman (Department of Pathology, Shaukat Khanum Cancer Hospital) ;
  • Mushtaq, Sajid (Department of Pathology, Shaukat Khanum Cancer Hospital) ;
  • Akhtar, Noreen (Department of Pathology, Shaukat Khanum Cancer Hospital)
  • Published : 2013.06.30


Background: The presence of Epstein-Barr virus (EBV) in Non-Hodgkin's lymphoma can be identified by immunohistochemistry for detection of EBV latent membrane protein (LMP). The role of EBV as an etiologic agent in the development of non-Hodgkin lymphoma has been supported by detection of high levels of latent membrane protein 1 (LMP-1) expression in tumors. However, no study has been conducted in a Pakistani population up till now to determine the frequency of Epstein-Barr virus positivity. The objective of our study was to determine a value for non-Hodgkin lymphoma patients using EBV LMP-1 immunostaining in our institution. Materials and Methods: This study was carried out at the Department of Histopathology, Armed Forces Institute of Pathology (AFIP), Pakistan from December 2011 to December 2012. It was a cross sectional study. A total of 71 patients who were diagnosed with various subtypes of NHL after histological and EBV LMP-1 immunohistochemical evaluation were studied. Sampling technique was non-probability purposive. Statistical analysis was achieved using SPSS version 17.0. Mean and SD were calculated for quantitative variables like patient age. Frequencies and percentages were calculated for qualitative variables like subgroup of NHL, results outcome of IHC for EBV and gender distribution. Results: Mean age of the patients was $53.6{\pm}16$ years (Mean${\pm}$SD). A total of 50 (70.4%) were male and 21 (29.6%) were female. Some 9 (12.7%) out of 71 cases were positive for EBV-LMP-1 immunostaining, 2 (22.2%) follicular lymphoma cases, 1 (11.1%) case of T-cell lymphoblastic lymphoma, 4 (44.4%) cases of diffuse large B cell lymphomas, 1 (11.1%) mantle cell lymphoma and 1 (11.1%) angioimmunoblastic T cell lymphoma case. Conclusion: In our study, frequency of EBV in NHL is 12.7% and is mostly seen in diffuse large B cell lymphoma. This requires further evaluation to find out whether this positivity is due to co-infection or has a role in pathogenesis.


  1. Matsushita H, Nakamura N, Tanaka Y, et al (2012). Clinical and pathological features of B-cell non-Hodgkin lymphomas lacking the surface expression of immunoglobulin light chains. Clin Chem Lab Med, 50, 1665-70.
  2. Mushtaq S, Akhtar N, Jamal S, et al (2008). Malignant Lymphomas in Pakistan According to WHO Classification of Lymphoid Neoplasms. Asian Pac J Cancer Prev, 9, 229-32.
  3. Morales D, Beltran B, De Mendoza FH et al (2010). Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma, 51, 66-72.
  4. Nourse JP, Crooks P, Keane C, et al (2012). Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. J Virol Methods, 184, 46-54.
  5. Oh YH, Park CK (2006). Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci, 21, 397-405.
  6. Oyama T, Yamamoto K, Asano N, et al (2007). Age-related EBVassociated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res, 13, 5124-32.
  7. Paydas S, Ergin M, Erdogan S, Seydaoglu G (2008). Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res, 32, 1424-30.
  8. Park S, Lee J, Ko YH et al (2007). The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood, 110, 972-78.
  9. Sjo LD, Poulsen CB, Hansen M, et al (2007). Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol, 79, 501-7.
  10. Tumwine LK, Orem J, Kerchan P, et al (2010). EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer, 5, 12.
  11. Veelken H, Vik Dannheim S, Schulte Moenting J, et al (2007). Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol, 18, 931-9.
  12. Williams H, Crawford DH (2006). Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood, 107, 862-69.
  13. Mao Y, Lu MP, Lin H, et al (2013). Prognostic Significance of EBV Latent Membrane Protein 1 Expression in Lymphomas: Evidence from 15 Studies. PLoS One, 8, 60313.
  14. Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al (2012). EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol, 25, 968-82.
  15. Ashraf MJ, Makarempour A, Monabati A, et al (2012). Comparison between presence of epstein barr virus in nodal and extra nodal diffuse large B cell lymphoma of head and neck, an Iranian experience. Iran Red Crescent Med J, 14, 764-70.
  16. Beltran BE, Morales D, Quinones P, et al (2011). EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk, 11, 512-6
  17. Chabay P, De Matteo E, Aversa Luis, et al (2002). Assessment of Epstein-Barr virus association with pediatric non-hodgkin lymphoma in immunocompetent and in Immunocompromised patients in Argentina. Arch Pathol Lab Med, 126, 331-5.
  18. Chabay P, De Matteo E, Lorenzetti M, et al (2009). Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series. Pediatr Dev Pathol, 12, 28-34.
  19. Fu K, Weisenburger DD, Choi WW, et al (2008). Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol, 26, 4587-94.
  20. George LC, Rowe M, Fox CP, et al (2012). Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. Curr Hematol Malig Rep, 7, 276-84.
  21. Gonin J, Larousserie F, Bastard C, et al (2011). Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS One, 6, 24617.
  22. Jamal S, Moghal S, Mamoon N, et al (2006). The pattern of malignant tumours: tumour registry data analysis, AFIP, Rawalpindi, Pakistan (1992-2001). J Pak Med Assoc, 56, 359-62.
  23. Karen DC, Christopher AL, Soeir Abdel-Latif E, et al (2004). Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol, 33, 1034-39.
  24. Malagon F, Gonzalez-Angulo J, Carrasco E, Robert L (2011). Etiopathogenesis of Burkitt's lymphoma: a lesson from a BL-like in CD1 mouse immune to Plasmodium yoelii yoelii. Infect Agent Cancer, 6, 10.

Cited by

  1. LMP1 Immunohistochemistry in Non-Hodgkin’s Lymphoma of Sudanese Cases vol.06, pp.02, 2016,
  2. The Polymerase Chain Reaction in Diagnosis of Small B-Cell Non-Hodgkin Lymphomas vol.17, pp.2, 2016,
  3. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: is it different between Over and Under 50 Years of Age? vol.17, pp.4, 2016,
  4. Epstein–Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland vol.64, pp.2, 2016,